Reviewer's report

Title: Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: A systematic review and meta-analysis

Version: 2  Date: 8 October 2014

Reviewer: Joshua Kantrowitz

Reviewer's report:

Major Compulsory Revisions

This is much improved, as the figures now match the text. The meta analysis My only remaining issue is with the suggestion that "Aripiprazole is limited to two studies and like risperidone may show diminished returns over time." The stamens is unclear may be misunderstood to suggest over time meaning chronic (as opposed to acute) treatment. This should be clarified, as I don't think this is what the authors mean.

The reference for this is general and potentially applies to all antipsychotics. Figure 5 (meta analysis of odds ratios) generally supports this assertion, but the meta analysis of YBOCs change does not.

If this statement is to be kept, the authors should offer an explanation as to why an odd's ratio meta analysis is only conducted for risperidone, speculate on the disparate findings, and moreover, there should be some explanation as to the specific link between risperidone's potential diminished returns and aripiprazole. However, I suggest removing the statement

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

Dr. Kantrowitz reports having received consulting payments within the last 36 months from Otsuka Pharmaceuticals ($400) for advice on the development of non-dopaminergic compounds.